Last Price | 58.70 | Max Price | 62.38 |
Min Price | 27.80 | 1 Year return | -59.98 |
Sector | Health Care | Subsector | Biotechnology |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 3 | 141,925 | 0.00 % |
2020 | 13 | 170,231 | 0.01 % |
2021 | 72 | 252,886 | 0.03 % |
2022 | 12 | 238,500 | 0.01 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
The period between December 2015 and December 2016 was a bad period for the investors. The stock lost almost 83 percent. Over the period 2011-2016 the stock lost a modest 0 percent. The net results between 2011 and 2015 were far from constant and fluctuated between -9,84 million dollars and -64,54 million dollars.
Mirati Therapeutics Inc is mostly active in the health care eq. & services sector. The period from 2006 till the end of 2016 the international sector gained around 102 percent. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-December 2016) there is a plus of 102 percent.
Mirati Therapeutics Inc didn't pay out any dividends (in the past 5 years).
At the end of 2015 the American company had a balance sheet of 128,02 million dollars. The total debt was around 9,84 million dollars. This is 7,69 percent of the total balance sheet. As per the end of 2015 Mirati Therapeutics Inc's price/earnings-ratio equaled -5. So investors paid for 1 stock -5 times the earnings per share of 2015. We could say that based on her price/earnings-ratio and dividend yield the American stock can be seen as a value stock.
The health care company's market capitalization (the number of shares outstanding times the market value) equaled around 508,41 million dollars. At the end of 2015 around 16,9 million stocks were listed.
All Mirati Therapeutics Inc's annual reports can be found here. More information about Mirati Therapeutics Inc can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
0
|
13
|
3
|
13
|
Costs |
65
|
83
|
70
|
111
|
217
|
371
|
Profit |
-65
|
-83
|
-70
|
-98
|
-213
|
-358
|
Margin of profit |
0.0
|
0.0
|
0.0
|
-761.18
|
-6385.03
|
-2671.19
|
ROI |
-54.61
|
-172.06
|
-49.15
|
-48.82
|
-55.78
|
-26.30
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
118
|
48
|
143
|
202
|
382
|
1,361
|
Debt |
10
|
15
|
14
|
27
|
50
|
115
|
Total assets |
128
|
63
|
157
|
228
|
432
|
1,476
|
Solvency |
92.31
|
76.15
|
91.12
|
88.24
|
88.45
|
92.19
|
Cash |
122
|
57
|
151
|
223
|
415
|
1,390
|
Cashflow |
-51
|
-68
|
-65
|
-70
|
-148
|
-272
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-5.15
|
-4.50
|
-4.64
|
-2.61
|
-2.96
|
-2.35
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
31.60
|
4.75
|
18.25
|
42.42
|
128.86
|
Eps |
-4.20
|
-2.78
|
-3.19
|
-5.69
|
-7.96
|
Price/earnings-ratio |
-7.52
|
-1.71
|
-5.72
|
-7.46
|
-7.37
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
2.42
|
5.01
|
6.20
|
9.67
|
26.98
|
Market to book |
0.08
|
1.05
|
0.34
|
0.23
|
0.46
|
Cashflow per stock |
-3.41
|
-2.26
|
-2.15
|
-3.74
|
-5.38
|
Stocks |
20
|
29
|
33
|
40
|
50
|
Market Cap |
630.01
|
135.96
|
593.83
|
1.676.32
|
2.960.78
|
Date
|
Price
|
---|---|
22 Mar 2024
|
58.70
|
18 Mar 2024
|
58.70
|
15 Mar 2024
|
58.70
|
12 Mar 2024
|
58.70
|
11 Mar 2024
|
58.70
|
09 Mar 2024
|
58.70
|
07 Mar 2024
|
58.70
|
01 Mar 2024
|
58.70
|
29 Feb 2024
|
58.70
|
27 Feb 2024
|
58.70
|
22 Feb 2024
|
58.70
|
21 Feb 2024
|
58.70
|
20 Feb 2024
|
58.70
|
15 Feb 2024
|
58.70
|
14 Feb 2024
|
58.70
|
13 Feb 2024
|
58.70
|
09 Feb 2024
|
58.70
|
08 Feb 2024
|
58.70
|
07 Feb 2024
|
58.70
|
06 Feb 2024
|
58.70
|
05 Feb 2024
|
58.70
|
01 Feb 2024
|
58.70
|
31 Jan 2024
|
58.70
|
30 Jan 2024
|
58.70
|
27 Jan 2024
|
58.70
|
25 Jan 2024
|
58.70
|
23 Jan 2024
|
58.70
|
16 Jan 2024
|
59.28
|
11 Jan 2024
|
58.90
|
10 Jan 2024
|
59.04
|